Advertisement
Loading...

Verastem, Inc.

2VSA.FXETRA
Healthcare
Biotechnology
4.39
-0.25(-5.46%)
German Market opens in 14h 36m

Verastem, Inc. Fundamental Analysis

Verastem, Inc. (2VSA.F) shows weak financial fundamentals with a PE ratio of -1.94, profit margin of -6.78%, and ROE of -18.50%. The company generates $0.0B in annual revenue with weak year-over-year growth of 2.09%.

Key Strengths

Cash Position59.60%
PEG Ratio0.00
Current Ratio3.09

Areas of Concern

ROE-18.50%
Operating Margin-5.50%
We analyze 2VSA.F's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -2325.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-2325.6/100

We analyze 2VSA.F's fundamental strength across five key dimensions:

Efficiency Score

Weak

2VSA.F struggles to generate sufficient returns from assets.

ROA > 10%
-84.99%

Valuation Score

Excellent

2VSA.F trades at attractive valuation levels.

PE < 25
-1.94
PEG Ratio < 2
0.00

Growth Score

Moderate

2VSA.F shows steady but slowing expansion.

Revenue Growth > 5%
2.09%
EPS Growth > 10%
17.49%

Financial Health Score

Moderate

2VSA.F shows balanced financial health with some risks.

Debt/Equity < 1
1.52
Current Ratio > 1
3.09

Profitability Score

Weak

2VSA.F struggles to sustain strong margins.

ROE > 15%
-1849.74%
Net Margin ≥ 15%
-6.78%
Positive Free Cash Flow
No

Key Financial Metrics

Is 2VSA.F Expensive or Cheap?

P/E Ratio

2VSA.F trades at -1.94 times earnings. This suggests potential undervaluation.

-1.94

PEG Ratio

When adjusting for growth, 2VSA.F's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values Verastem, Inc. at 7.12 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

7.12

EV/EBITDA

Enterprise value stands at -2.10 times EBITDA. This is generally considered low.

-2.10

How Well Does 2VSA.F Make Money?

Net Profit Margin

For every $100 in sales, Verastem, Inc. keeps $-6.78 as profit after all expenses.

-6.78%

Operating Margin

Core operations generate -5.50 in profit for every $100 in revenue, before interest and taxes.

-5.50%

ROE

Management delivers $-18.50 in profit for every $100 of shareholder equity.

-18.50%

ROA

Verastem, Inc. generates $-84.99 in profit for every $100 in assets, demonstrating efficient asset deployment.

-84.99%

Following the Money - Real Cash Generation

Operating Cash Flow

Verastem, Inc. generates limited operating cash flow of $-114.29M, signaling weaker underlying cash strength.

$-114.29M

Free Cash Flow

Verastem, Inc. generates weak or negative free cash flow of $-114.29M, restricting financial flexibility.

$-114.29M

FCF Per Share

Each share generates $-1.65 in free cash annually.

$-1.65

FCF Yield

2VSA.F converts -40.83% of its market value into free cash.

-40.83%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.94

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.001

vs 25 benchmark

P/B Ratio

Price to book value ratio

7.12

vs 25 benchmark

P/S Ratio

Price to sales ratio

10.94

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.52

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.09

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-18.50

vs 25 benchmark

ROA

Return on assets percentage

-0.85

vs 25 benchmark

ROCE

Return on capital employed

-0.98

vs 25 benchmark

How 2VSA.F Stacks Against Its Sector Peers

Metric2VSA.F ValueSector AveragePerformance
P/E Ratio-1.9429.94 Better (Cheaper)
ROE-1849.74%738.00% Weak
Net Margin-677.57%-575975.00% (disorted) Weak
Debt/Equity1.520.44 Weak (High Leverage)
Current Ratio3.094.49 Strong Liquidity
ROA-84.99%-15756.00% (disorted) Weak

2VSA.F outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Verastem, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-93.56%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

42.98%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

24.34%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ